Arthrogen selected the Center for Human Drug Research (CHDR) in Leiden to execute the first clinical trial with Arthrogen’s lead product ART-I02 in the course of the second half of 2016.
Today Arthrogen was honoured to welcome a visiting delegation of the Japanese Health Science Foundation. Arthrogen's Dr. Lisette Bevaart and Dr. Susanne Snoek presented the exciting Arthrogen program.
Today Arthrogen presented at the Bio-Europe 2015 conference in Münich. Arthrogen's COO Dr. Janneke Meulenberg presented our ART-I02 gene therapy product and its clinical trial program.
Arthrogen to present at the Bio Europe 2015 conference, November 2-4 in Munich, in the category Advanced Therapies/Regenerative Medicines.
Article in AMC Magazine. read more
Arthrogen invited for two presentations at the ESGCT, one poster and one oral presentation.
Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis. read more
Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02) Delivered via Intra-Articular Injection in Rhesus Monkeys with Collagen-Induced Arthritis. read more
Arthrogen presented at the ASGCT in New Orleans.